Home>Corporate>History History 2017-2019 2011-2016 2005-2010 1994-2004 The HLX01 (rituximab injection) of Shanghai Henlius approved for marketing at the beginning of 2019, becoming the first biosimilar drug in China. FCN-159 tablet, a new drug of a subsidiary of Fosun Pharma, was approved by the State Food and Drug Administration for clinical trials of advanced solid tumors. Fosun Pharma cooperated with Marubeni to develop the third-party healthcare market. Fosun Pharma invested US$106 million in Butterfly Network, Inc., for development of smartphone ultrasound imager. SPAQ-CO® Disp, a malaria prevention drug for children of Fosun Pharma, was pre-certified by the World Health Organization. Fosun Pharma被認定為上海市企業技術中心 2011年 Fosun Pharma獲上海普陀區科技系統先進基層黨組織獎項 1998-2000年 Fosun Pharma獲創稅千萬元企業獎項 1999年 Fosun Pharma獲1999年中證亞商中國最具發展潛力上市50強企業獎 1999年7月 Fosun Pharma獲普陀區先進黨組織獎 2000年